Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Erythema Gyratum Repens Treatment & Management

  • Author: H Harris Reynolds, MD; Chief Editor: Dirk M Elston, MD  more...
 
Updated: Apr 28, 2016
 

Medical Care

Topical steroids are of no benefit in erythema gyratum repens. Corticosteroid injections may improve the pruritus but reportedly do not change the appearance of the skin eruption.

 
Contributor Information and Disclosures
Author

H Harris Reynolds, MD Medical Department Head and Flight Surgeon, Training Air Wing SIX, Naval Air Station; Lieutenant, Medical Corps, United States Navy

Disclosure: Nothing to disclose.

Coauthor(s)

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Specialty Editor Board

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

Jeffrey P Callen, MD Professor of Medicine (Dermatology), Chief, Division of Dermatology, University of Louisville School of Medicine

Jeffrey P Callen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, American College of Rheumatology

Disclosure: Received income in an amount equal to or greater than $250 from: XOMA; Biogen/IDEC; Novartis; Janssen Biotech, Abbvie, CSL pharma<br/>Received honoraria from UpToDate for author/editor; Received honoraria from JAMA Dermatology for associate editor and intermittent author; Received royalty from Elsevier for book author/editor; Received dividends from trust accounts, but I do not control these accounts, and have directed our managers to divest pharmaceutical stocks as is fiscally prudent from Stock holdings in various trust accounts include some pharmaceutical companies and device makers for i inherited these trust accounts; for: Celgene; Pfizer; 3M; Johnson and Johnson; Merck; Abbott Laboratories; AbbVie; Procter and Gamble; Amgen.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Karen D Allen, MD Consulting Dermatologist, Private Practice

Karen D Allen, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology

Disclosure: Nothing to disclose.

Raul Del Rosario, MD Consulting Staff, Dermatopathology, Mission Hospital at Laguna Beach

Raul Del Rosario, MD is a member of the following medical societies: American Society for Clinical Pathology

Disclosure: Nothing to disclose.

Suzanne Kaneshiro, MD Private Practice, Honolulu, HI

Suzanne Kaneshiro, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Carrie L Kovarik, MD Assistant Professor of Dermatology, Dermatopathology, and Infectious Diseases, University of Pennsylvania School of Medicine

Carrie L Kovarik, MD is a member of the following medical societies: Alpha Omega Alpha

Disclosure: Nothing to disclose.

References
  1. Appell ML, Ward WQ, Tyring SK. Erythema gyratum repens. A cutaneous marker of malignancy. Cancer. 1988 Aug 1. 62(3):548-50. [Medline].

  2. Stone SP, Buescher LS. Life-threatening paraneoplastic cutaneous syndromes. Clin Dermatol. 2005 May-Jun. 23(3):301-6. [Medline].

  3. Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol. 2012 Jul 25. [Medline].

  4. Rongioletti F, Fausti V, Parodi A. Erythema gyratum repens is not an obligate paraneoplastic disease: a systematic review of the literature and personal experience. J Eur Acad Dermatol Venereol. 2014 Jan. 28 (1):112-5. [Medline].

  5. Forrester DM. Self-assembled multi-ring formations of glutamine and a possible link to erythema gyratum repens. Med Hypotheses. 2015 Jul. 85 (1):10-6. [Medline].

  6. Boyd AS, Neldner KH, Menter A. Erythema gyratum repens: a paraneoplastic eruption. J Am Acad Dermatol. 1992 May. 26(5 Pt 1):757-62. [Medline].

  7. Liau MM, Long V, Yang SS. Erythema gyratum repens: a paraneoplastic eruption. BMJ Case Rep. 2016 Mar 7. 2016:[Medline].

  8. da Silva JA, Mesquita Kde C, Igreja AC, Lucas IC, Freitas AF, de Oliveira SM, et al. Paraneoplastic cutaneous manifestations: concepts and updates*. An Bras Dermatol. 2013 Jan-Feb. 88(1):9-22. [Medline].

  9. Lomholt H, Thestrup-Pedersen K. Paraneoplastic skin manifestations of lung cancer. Acta Derm Venereol. 2000 May. 80(3):200-2. [Medline].

  10. Olsen TG, Milroy SK, Jones-Olsen S. Erythema gyratum repens with associated squamous cell carcinoma of the lung. Cutis. 1984 Oct. 34(4):351-3, 355. [Medline].

  11. Serrao V, Martins A, Ponte P, Baptista J, Apetato M, Feio AB. Erythema gyratum repens as the initial manifestation of lung cancer. Eur J Dermatol. 2008 Mar-Apr. 18(2):197-8. [Medline].

  12. Eubanks LE, McBurney E, Reed R. Erythema gyratum repens. Am J Med Sci. 2001 May. 321(5):302-5. [Medline].

  13. Samotij D, Szczech J, Bencal-Kusinska M, Reich A. Erythema gyratum repens associated with cryptogenic organizing pneumonia. Indian J Dermatol Venereol Leprol. 2016 Mar-Apr. 82 (2):212-3. [Medline].

  14. Cheesbrough MJ, Williamson DM. Erythema gyratum repens, a stage in the resolution of pityriasis rubra pilaris?. Clin Exp Dermatol. 1985 Sep. 10(5):466-71. [Medline].

  15. Bryan ME, Lienhart K, Smoller BR, Johnson SM. Erythema gyratum repens in a case of resolving psoriasis. J Drugs Dermatol. 2003 Jun. 2(3):315-7. [Medline].

  16. Günther R, Nasser S, Hinrichsen H, Fölsch UR. [Erythema gyratum repens: drug reaction following azathioprine administration in a patient with type I autoimmune hepatitis]. Med Klin (Munich). 2002 Jul 15. 97(7):414-7. [Medline].

  17. Dermitsu T, Sasaki K, Iida E, et al. Urticarial vasculitis presenting as erythema gyratum repens-like eruption. J Eur Acad Dermatol Venereol. 2009 Feb. 23(2):215-7. [Medline].

  18. Spierings NM, Natkunarajah J. Leucocytoclastic vasculitis presenting as an erythema gyratum repens-like eruption. Clin Exp Dermatol. 2016 Apr. 41 (3):320-2. [Medline].

  19. Jouary T, Lalanne N, Stanislas S, Vergier B, Delaunay M, Taieb A. Erythema gyratum repens-like eruption in mycosis fungoides: is dermatophyte superinfection underdiagnosed in cutaneous T-cell lymphomas?. J Eur Acad Dermatol Venereol. 2008 Nov. 22(10):1276-8. [Medline].

  20. Verma P, Samson S, Monk B. A curious eruption: erythema gyratum repens in resolving pustular psoriasis. J Eur Acad Dermatol Venereol. 2008 May. 22(5):637-8. [Medline].

  21. Fruchter R, Shaikh G, Myers KL, Eungdamrong NJ, Lee HS, Franks AG Jr. An erythema gyratum repens variant of bullous lupus erythematosus. JAAD Case Rep. 2016 Mar. 2 (2):111-3. [Medline].

  22. Hauschild A, Swensson O, Christophers E. Paraneoplastic bullous pemphigoid resembling erythema gyratum repens. Br J Dermatol. 1999 Mar. 140(3):550-2. [Medline].

  23. Caux F, Lebbe C, Thomine E, et al. Erythema gyratum repens. A case studied with immunofluorescence, immunoelectron microscopy and immunohistochemistry. Br J Dermatol. 1994 Jul. 131(1):102-7. [Medline].

Previous
Next
 
Erythema gyratum repens. Courtesy of Jeffrey P. Callen, MD.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.